SCHEMBL21296880

SCHEMBL21296880

CCOC(=O)c1nn[nH]c1Oc1cccc(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.44
CYP19A1 P11511 3/20 0.43
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 4/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
HPGDS O60760 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CACNA1F O60840 1/20 0.38
ABCB1 P08183 1/20 0.38
CACNA1D Q01668 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29692449 1.00 ELANE (0.44) ELANECYP19A1KDM4ECYP1A2MAPT
SCHEMBL23001771 0.86 F10 (0.41) ELANEKDM4ECYP1A2MAPTPOLB
SCHEMBL29891533 0.86 F10 (0.41) ELANEKDM4ECYP1A2MAPTPOLB
SCHEMBL21296961 0.85 MAPT (0.45) CYP19A1KDM4EMAPTPOLBMAPK1
SCHEMBL22795534 0.85 HPGDS (0.48) CYP19A1KDM4ECYP1A2MAPTPOLB
SCHEMBL21296861 0.84 MAPT (0.43) KDM4ECYP1A2MAPTPOLBGAA
SCHEMBL29799138 0.84 MAPT (0.43) KDM4ECYP1A2MAPTPOLBGAA
SCHEMBL21296986 0.83 HAO1 (0.53)
SCHEMBL21296974 0.83 MAPT (0.42) KDM4ECYP1A2MAPTPOLBGAA
SCHEMBL29692318 0.83 HAO1 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2025-06-12 US disclosed
US-12213976-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2025-02-04 US disclosed
CN-114980886-B Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2024-08-09 CN disclosed
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2023-04-13 US disclosed
US-11504367-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-11-22 US disclosed
CN-114980886-A Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2022-08-30 CN disclosed
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
EP-4017490-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES Oxalurx, Inc. (US) 2022-06-29 EP disclosed
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2021-02-25 US disclosed
WO-2021035196-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2021-02-25 WO disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX ELANE 653/4885CYP19A1 1777/4885KDM4E 3780/4885
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT ELANE 646/4885CYP19A1 1765/4885KDM4E 3804/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX ELANE 653/4885CYP19A1 1777/4885KDM4E 3780/4885
US-11504367-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT ELANE 646/4885CYP19A1 1765/4885KDM4E 3804/4885
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT ELANE 646/4885CYP19A1 1765/4885KDM4E 3804/4885
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT ELANE 646/4885CYP19A1 1765/4885KDM4E 3804/4885
US-12213976-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT ELANE 646/4885CYP19A1 1765/4885KDM4E 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.